Navigation Links
Additional Efficacy Data from Satraplatin SPARC Phase 3,Investigational Trial Presented at Annual Meeting of American,Urological Association

-- Median time to pain progression is 66.1 weeks for the satraplatin arm compared with 22.3 weeks for the placebo arm -- Hazard ratio of 0.64 (95% CI: 0.51-0.79, p<0.001), representing a 36% reduction in the relative risk of pain progression

MARTINSRIED/MUNICH, Germany, May 21, 2007 /PRNewswire-FirstCall/ -- PRINCETON, N.J., and BOULDER, Colo. -- GPC Biotech AG and Pharmion Corporation today announced the presentation of additional data from the double-blind, randomized satraplatin Phase 3 registrational trial, the SPARC trial (Satraplatin and Prednisone Against Refractory Cancer). The data are being presented today at the Annual Meeting of the American Urological Association (AUA) in Anaheim, California. The SPARC trial is evaluating satraplatin plus prednisone versus placebo plus prednisone in 950 patients with hormone-refractory prostate cancer (HRPC) whose prior chemotherapy has failed. An NDA for satraplatin is currently under priority review by the U.S. FDA.

"Patients with metastatic hormone-refractory prostate cancer frequently suffer from substantial pain associated with bone metastases. Thus, pain control for these patients constitutes a major challenge and is an important goal when caring for them," said Oliver Sartor, M.D., Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Associate Professor at Harvard Medical School, Boston, MA, and principal investigator of the SPARC trial, who is presenting the satraplatin data today. "In addition to the very encouraging results for progression-free survival demonstrating a 33% lower risk of progression compared to control, it is exciting to see that the SPARC trial results show that treatment with satraplatin also results in a statistically significant improvement in time to pain progression."

Data presented today showed that the median time to pain progression was 66.1 weeks for the satraplatin arm compared with 22.3 weeks for
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
2. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
3. Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139 Presented at EULAR
4. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
5. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
6. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
7. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
8. Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder
11. PTC Therapeutics Announces Additional Positive Interim Phase 2 Results of PTC124 in Duchenne Muscular Dystrophy
Post Your Comments:
(Date:9/22/2014)... Sept. 22, 2014 Children,s National Health ... Sept. 29 at 5 p.m. EDT for its ... in response to continued strong interest from inventors.  ... will be awarded to the winning presentations at ... Symposium hosted by Children,s National in October. For ...
(Date:9/22/2014)... and SHANGHAI , Sept. ... (BHG), a global knowledge leader in healthcare technology, ... to support healthcare innovation in China ... connected health technologies. Continua and BHG announced this ... being held this week in Washington, ...
(Date:9/22/2014)... , Sept. 22, 2014 ... of the "Global Ablation Technologies (Radiofrequency, Ultrasound, ... 2019" report to their offering. ... the global ablation technologies market has been divided ... ultrasound, microwave, cryotherapy, hydrothermal, and hydromechanical ablation technologies. ...
Breaking Medicine Technology:Calling all medical innovators: Submit your pediatric medical device pitch for Children's National competition by Sept. 29 2Calling all medical innovators: Submit your pediatric medical device pitch for Children's National competition by Sept. 29 3Continua and Borderless Healthcare Group Form Strategic Partnership, Launch the Healthcare Technology Innovation Center in Shanghai 2Continua and Borderless Healthcare Group Form Strategic Partnership, Launch the Healthcare Technology Innovation Center in Shanghai 3Continua and Borderless Healthcare Group Form Strategic Partnership, Launch the Healthcare Technology Innovation Center in Shanghai 4Global Ablation Technologies (Radiofrequency, Ultrasound, Irreversible Electroporation, Cryotherapy, Microwave) Market - Forecasts to 2019 2Global Ablation Technologies (Radiofrequency, Ultrasound, Irreversible Electroporation, Cryotherapy, Microwave) Market - Forecasts to 2019 3
(Date:9/23/2014)... A 2014 study supported by the ... has found that rising temperatures and hotter ... children developing kidney stones. Researchers based their findings ... U.S. cities, including Dallas, Atlanta, Philadelphia, Chicago and Los ... for kidney stones within a relatively short span – ...
(Date:9/23/2014)... 23, 2014 ClickFunnels 2.0 ... application has created a buzz of excitement throughout the ... this new software has caught the attention of HonestyFirstReviews.com’s ... her readers. , “The technical aspects of ... and development can be quite daunting,” reports Hendricks. “In ...
(Date:9/23/2014)... from the University of Toronto, directed by Drs. ... in normal vestibular nerves and vestibular schwannomas (VSs). ... negligible difference between VSs that sporadically occur and ... a genetic disorder; and 2) the overexpressed PI3K/AKT/mTOR ... excellent therapeutic target. Detailed findings of this study ...
(Date:9/23/2014)... PA (PRWEB) September 23, 2014 Rinovum ... home-use conception assistance device on the market cleared by ... in stores and online at http://www.storkotc.com . , ... dream of having a baby is delayed by infertility1 ... first step to optimize their chances to conceive. ...
(Date:9/23/2014)... 2014 Ale Gicqueau, President and Chairman ... Data Visualization for Clinical Trials at the upcoming ... Francisco on Friday, September 26, 2014. , PhUSE ... its inception, PhUSE has expanded from its roots as ... platform for the discussion of topics encompassing the work ...
Breaking Medicine News(10 mins):Health News:New Study Finds Link Between Higher Temperatures and Kidney Stones in the United States 2Health News:New Study Finds Link Between Higher Temperatures and Kidney Stones in the United States 3Health News:ClickFunnels 2.0 – Review Of Russell Brunson’s Sales Funnel Building Software Released 2Health News:Aberrant PI3K/AKT/mTOR pathway found in vestibular schwanommas may be therapeutic target 2Health News:Aberrant PI3K/AKT/mTOR pathway found in vestibular schwanommas may be therapeutic target 3Health News:First-Ever Conception Assistance Device FDA-Cleared for Home Use Launches U.S. OTC Sales -- The Stork® OTC Delivers Hope to Millions Struggling to Conceive A Child 2Health News:First-Ever Conception Assistance Device FDA-Cleared for Home Use Launches U.S. OTC Sales -- The Stork® OTC Delivers Hope to Millions Struggling to Conceive A Child 3Health News:First-Ever Conception Assistance Device FDA-Cleared for Home Use Launches U.S. OTC Sales -- The Stork® OTC Delivers Hope to Millions Struggling to Conceive A Child 4Health News:Clinovo Sponsors and Presents at Pharmaceutical Users Software Exchange (PhUSE) SDE in San Francisco 2
... , ... Automates Consumer Tracking and Claims Workflow to Help Organizations Take Control of Medicaid Waivers ... Reston, ... in integrated health and human services management, announced today the immediate availability of ...
... ... also understands the value of providing excellent customer service to their customers. The customer ... A recent award from third party evaluators at STELLAService, ranks Anjolee high in three ... ...
... ... increase in business as the reward for providing personalized service and customized medications. The ... medicine. , ... Scottsdale, AZ (PRWEB) May 5, 2010 -- While important veterinary drugs remain in ...
... ... Yagodich – podiatrists at Your Next Step in Ardmore and Paoli, Pennsylvania – excitedly ... patients that suffer from toenail fungus. , ... Ardmore and Paoli, Pennsylvania (Vocus) May 4, 2010 -- ...
... ... and teff provide important nutrients for the gluten-free diet, but Carol Fenster bakes with sorghum ... To celebrate May as National Celiac Awareness month, she offers a free sorghum-based cookbook, Gluten-Free ... , ...
... helped some with respiratory disease, but more study ... Treatment with the antibiotic azithromycin doesn,t improve the ... fibrosis, U.S. researchers report. , "A vicious cycle ... and premature death in patients with cystic fibrosis ...
Cached Medicine News:Health News:Harmony Information Systems Announces Availability of Harmony for Aging Waivers Edition 2Health News:Harmony Information Systems Announces Availability of Harmony for Aging Waivers Edition 3Health News:Anjolee Receives Stellar Customer Service Award from STELLAService 2Health News:Scottsdale Veterinary Pharmacy Celebrates Success in Business By Dodging Veterinary Drug Shortages 2Health News:Scottsdale Veterinary Pharmacy Celebrates Success in Business By Dodging Veterinary Drug Shortages 3Health News:Over 450 Patients Now Toenail Fungus Free Thanks to Your Next Step's New Toenail Fungus Laser Treatment Technology 2Health News:Carol Fenster Offers Tips for Gluten-Free Cooking with Sorghum: May is National Celiac Awareness Month 2Health News:Azithromycin Doesn't Always Help Lungs in Cystic Fibrosis Patients 2
The Select Series® Arterial Cannulae utilize a state-of-the-art dip-molding technology. This process allows molding of a one-piece, wire-wound cannula that is flexible and kink-resistant....
Intermittent catheter...
... assay is a rapid and accurate bedside test ... assisting the diagnosis and assessment of patients with ... speed and accuracy profit from a ... assay = 12 minutes. In emergency departments Point ...
... Focus from Thermo Labsystems was designed specifically ... Advanced features such as the new fast ... on microvolumes help to define this as ... The new interchangeable handle plate offers a ...
Medicine Products: